Company Overview and News
2018-09-24 seekingalpha - 1
Cobalt spot prices were slightly down in September but appear to have stabilized just below US$30/lb.
SIE PIO CLA PANRF CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR JRV SHERF CDU RGARF CHK MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE MALRY HBNRF MEI PIONF BPLNF GAL CZI AMSLF HMI MIN POS AUZ RNX GME FQVLF AQR PTNUF WCTXD FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL MALRF ARV
Australian Mines has made an agreement with a New York-based company for $12 million in funding that will be put towards completing the acquisition of the Flemington project in New South Wales.
AUZ JRV AMSLF
Australian Mines has scheduled four diamond drill holes to test the Arunta West iron oxide copper gold (IOCG) ore deposits at its copper-gold operation in Western Australia.
AUZ JRV AMSLF
Australian Mines Ltd (ASX:AUZ) (FRA:MJH) has scheduled four diamond drill holes to test an iron oxide copper gold (IOCG) target at its Arunta West project in Western Australia.
AUZ JRV IGO IIDDY AMSLF
MELBOURNE, July 30 (Reuters) - Australia’s Jervois Mining has bought almost 5 percent of shares in Ecobalt Solutions Inc , which is developing a high grade cobalt mine in the United States, days after two of its biggest shareholders called for management overhaul.
Jervois Mining (ASX:JRV) chief executive Bryce Crocker updates Proactive Investors on the company’s renewed strategic focus, following over 50 years listed on the ASX.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:JRV / JERVOIS MINING LIMITED on message board site Silicon Investor.
|JRVE - JARVIS ENTERTAINMENT GRP INC||JRVE - JARVIS ENTERTAINMENT GRP INC||JRVE - JARVIS ENTERTAINMENT GRP INC|